Artwork

İçerik Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !

37. Injectable Vs. Sublingual Buprenorphine

46:46
 
Paylaş
 

Manage episode 399348333 series 3378548
İçerik Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

59 bölüm

Artwork
iconPaylaş
 
Manage episode 399348333 series 3378548
İçerik Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Sonya Del Tredici and John Keenan, Sonya Del Tredici, and John Keenan veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

37. Injectable Vs. Sublingual Buprenorphine

In episode 37 we discuss an article comparing injectable and sublingual buprenorphine.

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine, Volume 66, 102311

We also discuss new data on the teratogenicity of fentanyl, and a new genetic test to identify the risk for opioid use disorder.

Genetics on Medicine Open: A novel syndrome associated with prenatal fentanyl exposure

FDA: FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder

----------

This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES.

----------

Episode 37 Credits:

----------

This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.

The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.

Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

  continue reading

59 bölüm

Tüm bölümler

×
 
Loading …

Player FM'e Hoş Geldiniz!

Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.

 

Hızlı referans rehberi